Research Paper Volume 13, Issue 5 pp 6849—6865

Association of HIF1-α gene polymorphisms with advanced non-small cell lung cancer prognosis in patients receiving radiation therapy

Yan Zhang1, , Jian Wang2, , Zhanzhan Li3, ,

  • 1 Department of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, Henan Province, China
  • 2 Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, Henan Province, China
  • 3 Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China

Received: August 14, 2020       Accepted: December 19, 2020       Published: February 17, 2021      

https://doi.org/10.18632/aging.202542
How to Cite

Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

We investigated the association between single nucleotide polymorphisms (SNPs) in the HIF1A gene and the prognosis of advanced non-small cell lung cancer (NSCLC) patients undergoing radiation therapy. Patient overall survival (OS) and progression-free survival (PFS) were analyzed. The rs11549465 TT genotype was associated with poor PFS (P<0.001) and OS (P=0.001). The rs2057482 TT genotype was also associated with poor PFS (P=0.002) and OS (P=0.007). Stratified analyses revealed that these associations occurred in patients with a smoking history, squamous cell carcinoma, and stage IIIA disease, as well as those receiving radiation therapy a radiation dose of ≥70 Gy. We found associations between SNPs and PFS but not OS in patients without a smoking history, other histological types, and stage IIIB disease, as well as those undergoing chemoradiotherapy with a radiation dose of <70 Gy. No associations were observed between rs11549467 or rs110873142 and NSCLC prognosis. These results suggest that HIF1A polymorphisms can be used as independent prognostic biomarkers for NSCLC patients receiving radiation therapy.

Abbreviations

ADC: adenocarcinoma; BMI: body mass index; CRT: three-dimensional conformal radiotherapy; CT: Computed Tomography; CI: confidence interval; DNA: deoxyribonucleic acid; HIF1-alpha: hypoxic induction factor 1-alpha; HR: hazard ratio; IMRT: intensity modulated radiotherapy; KPS: Karnofsky Performance Status; MST: mean survival time; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival; PCR: polymerase chain reaction; SNP: single nucleotide polymorphism; SCC: squamous cell carcinoma; TNM: Tumor Node Metastasis; VEGF: vascular endothelial growth factor.